Felty’s Syndrome: Favorable Response to Granulocyte-Macrophage Colony-Stimulating Factor in the Acute Phase

Ulrich Kaiser(University of Applied Sciences Landshut), K. Havemann(Philipps University of Marburg), Martine Klausmann(Praxis für Hämatologie und Onkologie), Gerald Kolb(Philipps University of Marburg), Karl-Heinz Pflüger(Evangelisches Diakoniekrankenhaus)

Acta Haematologica

February 19, 2009

10.1159/000204757

Cited by 5

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280

<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

|Blood|2021|170

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

|Blood|2009|157